1
|
Xu Y, Shrestha N, Préat V, Beloqui A. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Adv Drug Deliv Rev 2021; 175:113795. [PMID: 33989702 DOI: 10.1016/j.addr.2021.05.005] [Citation(s) in RCA: 58] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 05/05/2021] [Accepted: 05/07/2021] [Indexed: 12/13/2022]
Abstract
Oral administration is the most commonly used route for drug delivery owing to its cost-effectiveness, ease of administration, and high patient compliance. However, the absorption of orally delivered compounds is a complex process that greatly depends on the interplay between the characteristics of the drug/formulation and the gastrointestinal tract. In this contribution, we review the different preclinical models (in vitro, ex vivo and in vivo) from their development to application for studying the transport of drugs across intestinal barriers. This review also discusses the advantages and disadvantages of each model. Furthermore, the authors have reviewed the selection and validation of these models and how the limitations of the models can be addressed in future investigations. The correlation and predictability of the intestinal transport data from the preclinical models and human data are also explored. With the increasing popularity and prevalence of orally delivered drugs/formulations, sophisticated preclinical models with higher predictive capacity for absorption of oral formulations used in clinical studies will be needed.
Collapse
Affiliation(s)
- Yining Xu
- University of Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73 B1.73.12, 1200 Brussels, Belgium.
| | - Neha Shrestha
- University of Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73 B1.73.12, 1200 Brussels, Belgium.
| | - Véronique Préat
- University of Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73 B1.73.12, 1200 Brussels, Belgium.
| | - Ana Beloqui
- University of Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73 B1.73.12, 1200 Brussels, Belgium.
| |
Collapse
|
2
|
Gastrointestinally Digested Protein from the Insect Alphitobius diaperinus Stimulates a Different Intestinal Secretome than Beef or Almond, Producing a Differential Response in Food Intake in Rats. Nutrients 2020; 12:nu12082366. [PMID: 32784756 PMCID: PMC7468914 DOI: 10.3390/nu12082366] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 07/31/2020] [Accepted: 08/06/2020] [Indexed: 12/21/2022] Open
Abstract
In this study we compare the interaction of three protein sources—insect, beef, and almond—with the gastrointestinal tract. We measured the enterohormone secretion ex vivo in human and pig intestine treated with in vitro digestions of these foods. Insect and beef were the most effective in inducing the secretion of CCK, while almond was the most effective in inducing PYY in pig duodenum. In the human colon, almond was also the most effective in inducing PYY, and GLP-1 levels were increased by insect and beef. The three digested proteins reduced ghrelin secretion in pig duodenum, while only insect reduced ghrelin secretion in human colon. We also found that food intake in rats increased in groups fed a raw insect pre-load and decreased when fed raw almond. In conclusion, the insect Alphitobius diaperinus modulates duodenal and colonic enterohormone release and increases food intake in rats. These effects differ from beef and almond.
Collapse
|
3
|
Grau-Bové C, González-Quilen C, Terra X, Blay MT, Beltrán-Debón R, Jorba-Martín R, Espina B, Pinent M, Ardévol A. Effects of Flavanols on Enteroendocrine Secretion. Biomolecules 2020; 10:biom10060844. [PMID: 32492958 PMCID: PMC7355421 DOI: 10.3390/biom10060844] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 05/26/2020] [Accepted: 05/29/2020] [Indexed: 12/23/2022] Open
Abstract
Some beneficial effects of grape seed proanthocyanidin extract (GSPE) can be explained by the modulation of enterohormone secretion. As GSPE comprises a combination of different molecules, the pure compounds that cause these effects need to be elucidated. The enterohormones and chemoreceptors present in the gastrointestinal tract differ between species, so if humans are to gain beneficial effects, species closer to humans-and humans themselves-must be used. We demonstrate that 100 mg/L of GSPE stimulates peptide YY (PYY) release, but not glucagon-like peptide 1 (GLP-1) release in the human colon. We used a pig ex vivo system that differentiates between apical and basolateral intestinal sides to analyse how apical stimulation with GSPE and its pure compounds affects the gastrointestinal tract. In pigs, apical GSPE treatment stimulates the basolateral release of PYY in the duodenum and colon and that of GLP-1 in the ascending, but not the descending colon. In the duodenum, luminal stimulation with procyanidin dimer B2 increased PYY secretion, but not CCK secretion, while catechin monomers (catechin/epicatechin) significantly increased CCK release, but not PYY release. The differential effects of GSPE and its pure compounds on enterohormone release at the same intestinal segment suggest that they act through chemosensors located apically and unevenly distributed along the gastrointestinal tract.
Collapse
Affiliation(s)
- Carme Grau-Bové
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
| | - Carlos González-Quilen
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
| | - Ximena Terra
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
| | - M. Teresa Blay
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
| | - Raul Beltrán-Debón
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
| | - Rosa Jorba-Martín
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
- Servei de Cirurgia General i de l’Aparell Digestiu, Hospital Universitari Joan XXIII, 43005 Tarragona, Spain
| | - Beatriz Espina
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
- Servei de Cirurgia General i de l’Aparell Digestiu, Hospital Universitari Joan XXIII, 43005 Tarragona, Spain
| | - Montserrat Pinent
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
- Correspondence: ; Tel.: +34-97-755-9566
| | - Anna Ardévol
- MoBioFood Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, c/Marcel·lí Domingo nº1, 43007 Tarragona, Spain; (C.G.-B.); (C.G.-Q.); (X.T.); (M.T.B.); (R.B.-D.); (A.A.)
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain; (R.J.-M.); (B.E.)
| |
Collapse
|